ACCO BRANDS CORP (ACCO)

Sector: Industrials

    Home/Companies/ACCO/Annual Meeting

2026 Annual Meeting Analysis

ACCO BRANDS CORP · Meeting: May 19, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

8

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Nine Directors

1 FOR/8 AGAINST

Against Analysis

✗ AGAINST
Joseph B. BurtonTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; tenure since 2022 overlaps underperformance period; 5-year TSR mitigant not applicable (director joined 2022)

Mr. Burton has served since 2022, meaning his tenure fully overlaps the period of severe stock underperformance; ACCO's stock fell roughly 28% over three years while the industrial sector ETF (XLI) gained 69%, a gap of nearly 97 percentage points that far exceeds the 30-point trigger threshold for companies with negative absolute returns.

✗ AGAINST
Kathleen S. DvorakTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; long tenure since 2010 fully overlaps underperformance period; 5-year TSR also severely negative (-52.3% vs XLI) — no 5-year mitigant applies

Ms. Dvorak has served since 2010, giving her a tenure that spans the entire underperformance period; the company's 3-year stock decline of 28% against the industrial sector ETF (XLI) gain of 69% represents a gap of roughly 97 percentage points, well above the 30-point trigger, and the 5-year record (-52.3% for ACCO vs. strong ETF gains) provides no mitigating offset.

✗ AGAINST
Pradeep JotwaniTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; long tenure since 2014 fully overlaps underperformance period; 5-year TSR also severely negative — no 5-year mitigant applies

Mr. Jotwani has served since 2014 and his tenure fully encompasses the severe underperformance period; ACCO's 3-year stock return of negative 28% versus the XLI industrial sector ETF's gain of 69% produces a gap of approximately 97 percentage points, far exceeding the 30-point trigger threshold, and the 5-year TSR of negative 52% confirms this is not a short-term anomaly.

✗ AGAINST
Robert J. KellerTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; very long tenure since 2005 fully overlaps underperformance period; 5-year TSR also severely negative — no 5-year mitigant applies

Mr. Keller has been a director since 2005, making him one of the longest-tenured board members; ACCO's 3-year stock decline of 28% against the XLI industrial sector ETF's gain of 69% is a gap of roughly 97 percentage points, well beyond the 30-point trigger, and the deeply negative 5-year return of -52% for ACCO shareholders shows the underperformance is sustained, not temporary.

✗ AGAINST
Ron LombardiTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; tenure since 2018 fully overlaps underperformance period; 5-year TSR also severely negative — no 5-year mitigant appliesSitting CEO of Prestige Consumer Healthcare serving on outside board — overboarding check: Lombardi holds CEO role at Prestige and sits on ACCO board; policy flags sitting CEOs holding 2+ outside public board seats

Mr. Lombardi is currently the Chairman, President and CEO of Prestige Consumer Healthcare, and serving on the ACCO board constitutes an outside public company board seat; under our policy, a sitting CEO should not hold two or more outside public board seats because their primary obligation is to their own company's shareholders, and additionally ACCO's 3-year stock underperformance of roughly 97 percentage points versus the XLI industrial sector ETF (negative 28% vs. positive 69%) independently triggers an AGAINST vote.

✗ AGAINST
Graciela I. MonteagudoTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; tenure since 2016 fully overlaps underperformance period; 5-year TSR also severely negative — no 5-year mitigant applies

Ms. Monteagudo has served since 2016, and her tenure fully covers the underperformance period; ACCO's 3-year stock return of negative 28% compared to the XLI industrial sector ETF's gain of 69% results in a gap of approximately 97 percentage points, far exceeding the 30-point trigger threshold for companies with negative absolute returns, and the 5-year return of negative 52% confirms sustained underperformance.

✗ AGAINST
E. Mark RajkowskiTSR underperformance trigger: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold for negative absolute TSR; tenure since 2012 fully overlaps underperformance period; 5-year TSR also severely negative — no 5-year mitigant applies

Mr. Rajkowski, who became independent Chairman in 2024, has served on the board since 2012, meaning his tenure substantially overlaps the entire underperformance period; ACCO's 3-year stock decline of 28% against the XLI industrial sector ETF's gain of 69% is a gap of approximately 97 percentage points — well beyond the 30-point trigger — and the 5-year return of negative 52% for shareholders eliminates any 5-year mitigant.

✗ AGAINST
Thomas W. TedfordTSR underperformance trigger applies to executive directors: 3-year price return -27.7% vs XLI +69.0%, gap of -96.7pp exceeds 30pp threshold; joined board October 2023 — tenure exceeds 24 months as of May 2026 meeting date; policy states company officers who serve as directors are subject to the same TSR trigger as all other directors

Mr. Tedford joined the board in October 2023 as President and CEO, meaning his board tenure exceeds 24 months by the time of the May 2026 annual meeting, so the TSR exemption for newer directors does not fully apply; under our policy, executive directors including the CEO are subject to the same TSR trigger as independent directors, and ACCO's 3-year stock underperformance of roughly 97 percentage points versus the XLI industrial sector ETF far exceeds the 30-point threshold — this AGAINST vote on Mr. Tedford as a director is independent of the separate Say on Pay analysis.

For Analysis

✓ FOR
Elizabeth A. Simermeyer

Ms. Simermeyer joined the board in 2023, meaning she has served for less than 24 months as of the underperformance measurement period, which exempts her from the TSR underperformance trigger under our policy; she has relevant operating and marketing experience from senior roles at Ecolab and Procter & Gamble, and all attendance and independence requirements are met.

Eight of nine director nominees receive an AGAINST vote: seven long-tenured independent directors (Burton, Dvorak, Jotwani, Keller, Monteagudo, Rajkowski) and the CEO-director (Tedford) all trigger the TSR underperformance policy because ACCO's 3-year stock return of negative 28% trails the XLI industrial sector ETF by approximately 97 percentage points, far exceeding the 30-point trigger for companies with negative absolute returns, and the 5-year record of negative 52% eliminates any mitigating offset. Ron Lombardi additionally triggers the overboarding policy as a sitting CEO (of Prestige Consumer Healthcare) holding an outside board seat. Only Elizabeth Simermeyer, who joined in 2023 and falls within the 24-month new-director exemption, receives a FOR vote.

Say on Pay

✓ FOR

CEO

Thomas W. Tedford

Total Comp

$4,488,935

Prior Support

97.6%%

The CEO's total reported compensation of approximately $4.49 million is positioned below the 50th percentile of the company's peer group as disclosed in the proxy, which is consistent with benchmark expectations for a mid-small cap industrial company and does not exceed the policy's individual CEO threshold. Pay mix is strongly variable — approximately 85% of the CEO's target compensation is at-risk performance-based pay (including performance stock awards and annual incentives), well above the 50-60% minimum required by our policy. Although the annual bonus payout was only 10% of target due to the company missing nearly all its financial targets in 2025, this outcome actually reflects the incentive plan working as intended — executives received very little bonus because results were poor, which is appropriate pay-for-performance alignment, and the prior year's 97.6% shareholder support provides no basis for concern about the program structure.

Auditor Ratification

✓ FOR

Auditor

KPMG LLP

Tenure

N/A

Audit Fees

$3,302,420

Non-Audit Fees

$25,500

Non-audit fees (audit-related fees of $12,800 plus tax fees of $1,900 plus other fees of $10,800, totaling $25,500) represent less than 1% of total audit fees of $3,302,420, well below the 50% threshold that would raise independence concerns; KPMG is a Big 4 firm appropriate for a company of ACCO's size; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, and no material restatements were identified.

Overall Assessment

The 2026 ACCO Brands annual meeting ballot presents significant governance concerns: eight of nine director nominees receive an AGAINST vote driven primarily by severe and sustained stock underperformance — ACCO's shares lost roughly 28% over three years while the XLI industrial sector ETF gained 69%, a gap of approximately 97 percentage points that far exceeds the policy trigger threshold, with the 5-year record of negative 52% confirming no short-term mitigant applies. The Say on Pay vote receives a FOR because the CEO is paid below peer median, the pay program is heavily performance-based, and the 2025 annual bonus paying out at only 10% of target demonstrates the incentive plan is working correctly; the auditor ratification also receives a FOR given minimal non-audit fees and an appropriate Big 4 auditor.

Filing date: March 27, 2026·Policy v1.2·high confidence

Compensation Peer Group

18 companies disclosed in 2026 proxy filing

AWIArmstrong World Industries, Inc.
BRCBrady Corporation
CMPRCimpress plc
CRSRCorsair Gaming Inc.
DLXDeluxe Corporation
EPCEdgewell Personal Care Company
ENREnergizer Holdings, Inc.
HELEHelen of Troy Limited
HNIHNI Corporation
TILEInterface, Inc.
MATVMativ Holdings, Inc.
MATWMatthews International Corp
MLKNMillerKnoll, Inc.
PBIPitney Bowes Inc.
SONOSonos Inc.
SPBSpectrum Brands Holdings, Inc.
SCSSteelcase Inc.
SMGThe Scotts Miracle-Gro Company